SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

?50m Floating Rate Notes due 2013

14 Oct 2008 12:52

RNS Number : 8049F
Rentokil Initial PLC
14 October 2008
 



Rentokil Initial plc

£50m Floating Rate Notes due 2013

Rentokil Initial plc (the "Company") announces that it has entered into a commitment with an investor who will purchase £50m Floating Rate Notes due 2013 (the "FRNs"). The FRNs are expected to be issued at par under the Company's existing Euro Medium Term Note Programme and carry a coupon of LIBOR + 3.25%.  The FRNs are expected to be issued before the end of October 2008 and to be guaranteed by Rentokil Initial 1927 plc, a wholly owned subsidiary of the Company.

Rentokil Initial 1927 plc currently guarantees the obligations of the Company to its bondholders, banks and certain other financial counterparties. These guarantees were due to expire on 19 November 2008 but will now be extended to match the maturity of the Company's £300 million 5.75 per cent. Notes due 2016, issued by the Company in March 2006, and the FRNs, whichever maturity is the later.

During the last two months, Rentokil Initial has announced the issue of £125m of new debt securities (being the FRNs and the £75 million Floating Rate Reset Notes due 2033 (the "PCRs")). The Company's £250m 6.125 per cent. notes due 2008 (the "Notes") will mature on 19 November 2008 and will be repaid from the Company's bank facilities. The Company estimates that it will have at least £350m of headroom in its committed facilities after repaying the Notes.  At least £100m of that headroom is provided by a facility which is due to expire in 2012. The balance is provided by a second facility which is extendable at the Company's option to January 2010. 

After November 2008, the next maturity of the Company's bond indebtedness will be in 2013 if the holders of the PCRs exercise their right to require repayment.

For further information

Shareholder/analyst enquiries:

Katharine Rycroft, Head of Investor Relations Rentokil Initial plc 020 7592 2700

Media enquiries:

Malcolm Padley, Head of Corporate Communications Rentokil Initial plc 020 7592 2700

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFFUFFLSASELS
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.